Abstract:Importance: A global outbreak of clade IIb Monkeypox virus (MPXV) infections spread rapidly across at least 118 countries resulting in a Public Health Emergency of International Concern (PHEIC) from July 2022 to May 2023. This outbreak affected more than 99 000 persons worldwide and caused more than 33 000 infections and 60 deaths in the US. In 2024, there have been approximately 200 new infections per month in the US. On August 14, 2024, the World Health Organization declared mpox a PHEIC for a second time due to a rapid increase in infections with clade I MPXV in Central Africa. Observations: Mpox is primarily acquired through direct skin to skin contact with MPXV. With clade IIb MPXV, infections are most commonly associated with sexual activity among individuals who are gay, bisexual, and other men who have sex with men. After a median incubation period of 7 to 10 days, prodromal symptoms include fever (62%-72%), lymphadenopathy (56%-86%), myalgias (31%-55%), malaise (23%-57%), and headache (25%-55%). Skin lesions progress through 4 well-defined stages (macules, papules, vesicles, and pustules) over 2 to 4 weeks. Clade IIb MPXV is typically a self-limited illness with a low mortality rate (<0.2% in the US); however, severe illness and death may occur in immunocompromised individuals, especially those with advanced HIV (CD4 count <200 cells/μL). Mpox should be suspected in patients with potential exposure to MPXV who have skin lesions, and the diagnosis is confirmed with polymerase chain reaction testing of lesions. Management is supportive and focuses on skin care and symptom relief with analgesics. While no antiviral treatments are currently approved for mpox by the US Food and Drug Administration, several therapeutics, such as tecovirimat, brincidofovir, and vaccinia immune globulin intravenous, are available through expanded access programs or clinical trials. Vaccination with the 2-dose Modified Vaccinia Ankara-Bavarian Nordic vaccine is recommended for high-incidence populations and has an efficacy of 66% to 86%. Conclusions and relevance: Mpox is a viral infection transmitted primarily through close skin to skin contact that typically causes a self-resolving illness but can result in severe illness and death in immunocompromised individuals. First-line therapy is supportive care, although patients with severe mpox infection may be treated with advanced therapeutics. Mpox vaccination is effective and, if available, should be offered to individuals at risk of exposure to mpox.

Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes

Mpox Clinical Presentation, Diagnostic Approaches, and Treatment Strategies: A Review

Mpox treatment evolution: past milestones, present advances, and future directions

Mpox global health emergency: Insights into the virus, immune responses, and advancements in vaccines PART II: Insights into the advancements in vaccines

The Current State and Progress of Mpox Vaccine Research

Advancements in monkeypox vaccines development: a critical review of emerging technologies

Mpox: what sexual health physicians need to know?

Mpox (formerly monkeypox): pathogenesis, prevention, and treatment

Update on monkeypox virus infection: Focusing current treatment and prevention approaches

Mpox global health emergency: Insights into the virus, immune responses, and advancements in vaccines PART I: Insights into the virus and immune responses

Progress and prospects on vaccine development against monkeypox infection

Concurrent outbreaks of mpox in Africa—an update

Review of the prevalence, diagnostics, and containment measures of the current mpox outbreak

Current Status of Vaccine Development for Monkeypox Virus

Human monkeypox virus: Epidemiologic review and research progress in diagnosis and treatment

Mpox and Lessons Learned in the Light of the Recent Outbreak: A Narrative Review

Monkeypox (mpox) virus: Classification, origin, transmission, genome organization, antiviral drugs, and molecular diagnosis

Mpox in People With Human Immunodeficiency Virus: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort

Differential Diagnosis, Prevention, and Treatment of mpox (Monkeypox): A Review for Dermatologists

Mpox: Special Considerations in the Immunocompromised Host

Research progress of Monkeypox and its current prevention and treatment options